Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. - Wikidata - wikimedia - TriplyDB

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

http://www.wikidata.org/entity/Q34827307

about

Expression and regulation of cornified envelope proteins in human corneal epithelium Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2 Effects of the regulatory ligands calcium and GTP on the thermal stability of tissue transglutaminase.Transglutaminase 2 mediates polymer formation of I-kappaBalpha through C-terminal glutamine cluster.Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.Transglutaminases (TGs) in ocular and periocular tissues: effect of muscarinic agents on TGs in scleral fibroblasts.Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report.Alpha1B-adrenoceptor signaling and cell motility: GTPase function of Gh/transglutaminase 2 inhibits cell migration through interaction with cytoplasmic tail of integrin alpha subunits.Transglutaminase II/microRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis.Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.The promotion of functional urinary bladder regeneration using anti-inflammatory nanofibers New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase.Roles of transglutaminases in cardiac and vascular diseases.Airway epithelial cells initiate the allergen response through transglutaminase 2 by inducing IL-33 expression and a subsequent Th2 response.Epithelial regulation of eicosanoid production in asthma.Transglutaminase activation in neurodegenerative diseases.Transglutaminases and neurodegeneration.Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.Doxorubicin induces the persistent activation of intracellular transglutaminase 2 that protects from cell death Intimal hyperplasia in loop-injured carotid arteries is attenuated in transglutaminase 2-null mice.Potential of transglutaminase 2 as a therapeutic target.Beta-Sheet-Forming, Self-Assembled Peptide Nanomaterials towards Optical, Energy, and Healthcare Applications.Emerging small-molecule compounds for treatment of atopic dermatitis: a review.The proteomic profile of a mouse model of proliferative vitreoretinopathy.An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.Trappin ovine molecule (TOM), the ovine ortholog of elafin, is an acute phase reactant in the lung.Transglutaminases: new target molecules for inflammatory bowel disease?Thermodynamics of binding of regulatory ligands to tissue transglutaminase.Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy.Clara cell protein 16 (CC16) serum levels in infants during respiratory syncytial virus infection.An overview of the first 50 years of transglutaminase research.Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family.Simulated environmental criticalities affect transglutaminase of Malus and Corylus pollens having different allergenic potential

P2860

Q24321302-6711624F-AB07-4A7C-BAE4-EC9B03FA8B18 Q28261578-8E9412F2-06F4-40F2-B452-E9F24B7AB849 Q30404253-5515D2AC-1856-4FD1-A55F-89FC8F3FD262 Q33258202-0285C8CB-C202-468A-87A5-A46656B3CA92 Q33522235-DA7944F3-2F19-4922-B6DB-90952EA2A28D Q33635140-2D3AB54F-33AD-40CC-A4C1-CFF0A4340EDF Q33873741-621CE9F3-EC6E-455E-9E88-2EB209366519 Q34072266-1C7E2EB6-C497-4A57-B4DB-94DE36782AD0 Q34329442-F1AC6E79-7EC6-40DE-B3D3-D284C6CD582F Q34396703-5D60B606-3FA5-4268-ACE4-A01C971F55A0 Q34449739-E70C5D90-D3DF-4957-8D6D-197FD14DF391 Q34722403-CF891D4E-7365-4EA5-A1B4-17C59E6B0C82 Q35038183-0F6E0BD3-CDFD-4497-952A-2F3186CA07B9 Q36664166-2D269392-57FF-425D-804A-2846D82B3451 Q36698336-45366453-F7A0-4B81-81F6-82E92E891F3B Q36768951-9DFB9B0E-D421-4A68-A0AF-25CBA7284A1B Q37352964-3D3378AA-2253-4E97-88FA-210F956B25F3 Q37365083-DC5CB20E-35F5-457B-AE18-78D7C6B25370 Q37406648-0D6B0E60-8F60-43C2-8BE9-7AB8B2D1BB82 Q37461477-3CCEC034-8597-4D55-91BB-EC1CEC4793CE Q37622205-C61934A2-9041-4755-B909-88AC33A66F92 Q37776508-725B3716-E00D-4954-9849-9BA2B25BF404 Q38452137-8BA21E38-6A8C-4BB9-B4A9-110784795E3E Q38607958-2E1FECDC-716A-40BC-838D-1C2E12A37DD9 Q38637844-0F010DF8-10F3-4E4F-A89F-A6FAC6BDB9BF Q38909557-9AA55819-3DE9-424D-B927-5D64AA57487A Q39162858-0ABF884B-2E17-40BC-8F04-8A3A2235FC91 Q40528803-5B0A8417-F24C-4F3D-BFFB-68DB57E81149 Q42207209-C5EF6850-41D7-4B6A-AA19-D50332017487 Q43208594-FC3A08FA-5818-4EDB-8056-B14DE0721B11 Q44329023-913E8AB4-B480-4EAB-B6A5-9C4DEE3FE094 Q45388995-B7889EA1-9242-4382-AD5C-AAFBCAF24434 Q53123205-ADE26BC3-58EB-485E-9A65-262C1C9E3F98 Q55499802-AE26AC5D-ED13-4A95-B73F-5B1E9A3173F6 Q56982661-303FC8EF-B43F-48C7-800D-48B6A2E0AD1D

P2860

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

http://www.wikidata.org/entity/Q34827307

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@ast

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@en

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@nl

type

label

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@ast

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@en

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@nl

prefLabel

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@ast

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@en

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@nl

P1433

Q34827307-164E5563-B153-4D53-9BF9-B9C330E23DE3

P1476

Q34827307-F9D4B18F-AE12-4C8C-B8F9-EB54EC910452

P2093

Q34827307-48C71D34-F995-444A-9442-39C1D98FB668

Q34827307-9292378A-946B-4C16-B5D5-8BE2484116A0

Q34827307-F032D99E-CFBB-469A-A4D1-58E20D4505D4

Q34827307-FD51EDD9-6A19-4BED-AE99-9A5CA815581D

Q34827307-FE9A5B0C-1C74-4767-9D3C-9C95F5C44238

P2860

Q34827307-08BE5A2F-C275-49C0-A0D0-506089A0ADB5

Q34827307-15358A67-ACDD-4B1C-A593-3C4E27290713

Q34827307-190E782B-16D8-4EED-A9AF-C5D70D9108E7

Q34827307-1C6149B2-BD31-41A8-ADF8-BA99184030C9

Q34827307-20111F14-DC01-416F-BCCA-995289E1BEEB

Q34827307-2F0AD301-4F45-4531-BBFB-A01DAB87BA51

Q34827307-2F654B9D-7DBC-4693-922D-F322C70DDB70

Q34827307-33255E71-6AD8-462D-9B1A-BB8F4D44E87C

Q34827307-47CEE62C-9DFE-496A-B8F1-5AFBFCEEA838

Q34827307-5846C2E4-8718-46A3-B40A-FF0B550793A2

P304

Q34827307-B2D32B0C-B740-453A-B463-1EF8E0A6345E

P31

Q34827307-B554535E-2A97-4601-BDC1-7AF2B64A88ED

P356

Q34827307-7A12D87D-4EFC-4E59-85FE-45317DD1F30C

P407

Q34827307-3DFF777D-C8C2-4453-8B79-46FB37DDEB89

P433

Q34827307-A6E46745-987A-4A57-B6EE-334B7B36C3F9

P478

Q34827307-634F9CEA-BD01-4507-B53F-18417ADDE249

P577

Q34827307-C61B510C-25B5-450B-A265-3479F1B5298B

P698

Q34827307-287EB9FB-130C-4B25-9370-160AAC380DC4

P921

Q34827307-0C8A9001-CA8D-43BB-8867-FAC81065DC3E

P932

Q34827307-895125AA-16D0-42B8-B457-6CC69AA4D6CC

P356

P1433

Journal of Clinical Investigation

P1476

Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

@en

P2093

Joo-Yong Kim

http://www.w3.org/2001/XMLSchema#string

Joonhong Sohn

http://www.w3.org/2001/XMLSchema#string

Soo-Youl Kim

http://www.w3.org/2001/XMLSchema#string

Tae-Im Kim

http://www.w3.org/2001/XMLSchema#string

Young-Hee Yoon

http://www.w3.org/2001/XMLSchema#string

P2860

Small proline-rich protein 1 is the major component of the cell envelope of normal human oral keratinocytes

Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity

Uteroglobin/Clara cell 10-kDa family of proteins: nomenclature committee report

SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking

A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP

IFN-gamma induces transglutaminase 2 expression in rat small intestinal cells

The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope

Antiflammin-2 prevents HL-60 adhesion to endothelial cells and prostanoid production induced by lipopolysaccharides.

Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases.

Antiflammin peptides in the regulation of inflammatory response.

P304

121-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI200315937

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12511595

http://www.w3.org/2001/XMLSchema#string

P921

P932

151832

http://www.w3.org/2001/XMLSchema#string